Registration for ASGCT's 28th Annual Meeting is NOW OPEN! Join us May 13-17 in New Orleans for the premier event in CGT.
Learn about new approvals and the state of the field for each quarter of 2021.
Globally, there are now 3,483 gene, cell, and RNA therapies in development from preclinical through pre-registration stages. Q4 2021 highlights: approval of a new cell therapy and a new RNA therapy in the U.S., and much more!
New in Q3: two new gene therapies in the European Union (EU) and China, the expansion of two gene therapy approvals to new regions (South Korea and the EU), the continued growth ingene therapy research, and the latest on RNA therapeutic studies of anti-infective prophylactic vaccines.
Highlights in the second quarter of 2021 include the approval of a new gene therapy in Japan, the expansion of gene therapy approvals to three new countries, and more!
The data show unequivocally that gene, cell, and RNA therapies continue to grow rapidly with nearly 3,500 therapies in preclinical and clinical development throughout the world.
January 22-23, 2025 | Virtual
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico